Oedema Clinical Trials

49 recruitingLast updated: June 18, 2026

There are 49 actively recruiting oedema clinical trials across 39 countries. Studies span Not Applicable, Phase 3, Phase 4, Phase 2, Phase 1. Top locations include St Louis, Missouri, United States, London, United Kingdom, Cincinnati, Ohio, United States. Updated daily from ClinicalTrials.gov.


Oedema Trials at a Glance

49 actively recruiting trials for oedema are listed on ClinicalTrialsFinder across 6 cities in 39 countries. The largest study group is Not Applicable with 7 trials, with the heaviest enrollment activity in St Louis, London, and Cincinnati. Lead sponsors running oedema studies include Takeda, University Hospital, Grenoble, and CSL Behring.

Browse oedema trials by phase

Treatments under study

About Oedema Clinical Trials

Looking for clinical trials for Oedema? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Oedema trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Oedema clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 49 trials

Recruiting
Phase 3

STOP-HAE: A Phase 3 Study of ADX-324 in HAE

Hereditary AngioedemaHereditary Angioedema - Type 1Hereditary Angioedema - Type 2+1 more
ADARx Pharmaceuticals, Inc.90 enrolled51 locationsNCT06960213
Recruiting
Phase 3

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)Hereditary Angioedema - Type 1Hereditary Angioedema - Type 2+1 more
ADARx Pharmaceuticals, Inc.90 enrolled48 locationsNCT07428499
Recruiting

A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)

Hereditary Angioedemas
CSL Behring200 enrolled22 locationsNCT07001280
Recruiting
Phase 3

Donidalorsen Treatment in Children With Hereditary Angioedema

Hereditary Angioedema (HAE)
Ionis Pharmaceuticals, Inc.20 enrolled10 locationsNCT07298447
Recruiting
Not Applicable

A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema

Hereditary Angioedema (HAE)
Takeda514 enrolled1 locationNCT07293364
Recruiting
Phase 3

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

Hereditary Angioedema (HAE)
Pharvaris Netherlands B.V.170 enrolled62 locationsNCT06679881
Recruiting

A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in the Kingdom of Saudi Arabia

Hereditary Angioedema (HAE)
Takeda50 enrolled1 locationNCT07263685
Recruiting
Phase 3

Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency

Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
Pharvaris Netherlands B.V.32 enrolled17 locationsNCT07266805
Recruiting
Phase 3

A Study of Navenibart in Participants With Hereditary Angioedema

Hereditary Angioedema (HAE)
Astria Therapeutics, Inc.145 enrolled87 locationsNCT06842823
Recruiting

A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries

Hereditary Angioedema (HAE)
Takeda40 enrolled24 locationsNCT07251933
Recruiting

Measuring Fluid Buildup in Cancer Patients

OedemaChemotherapyCancer+4 more
Jens Rikardt Andersen46 enrolled1 locationNCT07443618
Recruiting
Not Applicable

Deployment o the Multidisciplinary Prospective Cohort Imminent

Severe AsthmaMultiple SclerosisAtopic Dermatitis+6 more
University Hospital, Lille2,200 enrolled1 locationNCT04334031
Recruiting

Validation and Clinical Utility of the Lung Sliding Index (LSI) for Differentiating Pulmonary Diseases

PneumothoraxCOPDPneumonia+4 more
Assiut University700 enrolled1 locationNCT06983366
Recruiting
Phase 4

Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab

Hereditary Angioedema
CSL Behring30 enrolled11 locationsNCT06806657
Recruiting

Real-life Ecological Momentary Assessment of Lived Burden in Hereditary AngioEdema

Hereditary Angioedema With C1 Esterase Inhibitor DeficiencyHereditary Angioedema - Type 1Hereditary Angioedema - Type 2
Istituti Clinici Scientifici Maugeri SpA30 enrolled1 locationNCT07448181
Recruiting

Deep Phenotyping of CIndU

Skin DiseasesAngio-Oedema and/or Urticaria
Centre for Human Drug Research, Netherlands40 enrolled3 locationsNCT07359430
Recruiting

Institutional Registry of Rare Diseases

ParagangliomaPheochromocytomaAmyloidosis+23 more
Hospital Italiano de Buenos Aires380 enrolled1 locationNCT06573723
Recruiting

Oedema Study : Chroedem

Lower limb Chronic Oedema
University Hospital, Montpellier60 enrolled3 locationsNCT02914808
Recruiting
Phase 3

Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns

Severe Diabetic Macular Oedema
Belfast Health and Social Care Trust264 enrolled22 locationsNCT06985706
Recruiting
Not Applicable

Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery

Cataract SurgeryNSAID (Non-Steroidal Anti-Inflammatory Drug)Macular Oedema
Nemocnice Kolín150 enrolled1 locationNCT07178639